remibrutinib
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune and Chronic Inflammatory Diseases
Conditions
Autoimmune and Chronic Inflammatory Diseases
Trial Timeline
Jul 23, 2025 → Oct 14, 2025
NCT ID
NCT07032272About remibrutinib
remibrutinib is a phase 1 stage product being developed by Novartis for Autoimmune and Chronic Inflammatory Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT07032272. Target conditions include Autoimmune and Chronic Inflammatory Diseases.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune and Chronic Inflammatory Diseases were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170724 | Pre-clinical | Active |
| NCT07456891 | Phase 3 | Recruiting |
| NCT07032272 | Phase 1 | Completed |
| NCT05976243 | Phase 3 | Active |
Competing Products
20 competing products in Autoimmune and Chronic Inflammatory Diseases